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The Gram-negative bacterium Burkholderia pseudomallei is a serious environmental
pathogen and the causative agent of the often fatal melioidosis. Disease occurs
following exposure to contaminated water or soil, usually through cuts in the skin
or via inhalation. However, the underlying mechanisms of pathogenicity remain poorly
understood. B. pseudomallei is endemic to South East Asia and Northern Australia where
infections are associated with antibiotic resistance and high mortality rates. Categorization
of the pathogen as a potential biowarfare agent has also made research into vaccine
development a high priority. Recent genome-scale screening has produced a large number
of putative gene candidates from B. pseudomallei with the potential for development
into vaccines. This mini-review will discuss the advantages and limitations of this novel
approach, how these new techniques can complement existing strategies, and outline
aims for future research.
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INTRODUCTION
Burkholderia pseudomallei is a serious environmental pathogen of
man and the causative agent of the often fatal disease melioido-
sis. Infection occurs following exposure to contaminated water or
soil, usually through cuts in the skin or via inhalation, but the
underlying mechanisms of pathogenicity of B. pseudomallei to
humans remain poorly understood (Adler et al., 2009). B. pseu-
domallei is endemic to South East Asia and Northern Australia
where infections are associated with both antibiotic resistance
and high patient mortality (∼50%). The high rates of infection
and subsequent mortality make B. pseudomallei a high prior-
ity for research and vaccine development, as no effective vaccine
currently exists. A combination of the lack of vaccine, high infec-
tion rate via aerosol inhalation, and limited utility of antibiotics
has resulted in classification of this bacterium as a Category B
biowarfare pathogen (Rotz et al., 2002).
During the establishment of infection B. pseudomallei adheres
to, survives and replicates within both host epithelial cells and
macrophages. The bacterium is therefore capable of interfering
with the host cellular mechanisms that would otherwise destroy
it. Known bacterial factors affecting this interaction with host
cells include the bacterial capsule, and effectors delivered by the
type III and type VI secretion systems (T3SS and T6SS) (Stevens
et al., 2003; Shalom et al., 2007; Galyov et al., 2010; Burtnick
et al., 2011). Once inside the macrophage the pathogen induces
cell fusion leading to the formation of “Multi-Nucleated Giant
Cells” or MNGCs, a process key to both intracellular replica-
tion and bacterial persistence (Kespichayawattana et al., 2000).
Following the invasion of host cells pathogen replication reaches
a critical point at which the bacteria induce cell death and are
released to establish secondary infections (Adler et al., 2009).
Both the intrinsic drug resistance and the intracellular lifestyle
of B. pseudomallei make successful antibiotic treatment difficult
therefore vaccine development is an important strategy against
melioidosis.
CHALLENGING MACROPHAGES TO IDENTIFY ANTI-IMMUNE
CELL FACTORS
Evidence suggests that macrophages are an essential early defence
against Burkholderia infection (Breitbach et al., 2006). These
innate immune cells are one of the first responding phagocytes
to arrive at the site of infection where they phagocytose invad-
ing bacteria and (along with other cells) release chemokines
and cytokines to govern immune responses and promote adap-
tive immunity. To establish intracellular infection Burkholderia
must evade macrophage killing and disrupt the normal cell
signaling and regulation processes. In order to detect poten-
tial vaccine candidates a simple “gain of function” screen was
designed aimed at identifying genes encoding anti-macrophage
virulence factors across the B. pseudomallei genome (Figure 1).
This screen identifies recombinantly expressed genes that equip
naïve Escherichia coli with anti-macrophage abilities in three
different ways: (1) the production of cytotoxic moieties e.g.,
proteins, secondary metabolites (toxins, effectors), (2) the abil-
ity to evade phagocytosis or destruction within the phagolyso-
some (intracellular survival), and (3) overwhelming e.g., nutrient
depletion and starvation (biofilm formation, hydrogen peroxide
scavenging) (Dowling et al., 2010).
POTENTIAL VACCINE CANDIDATES IDENTIFIED
A large proportion of melioidosis vaccines tested to date have
focused on the use of live-attenuated strains of B. pseudoma-
llei. However, a major issue with live-attenuated vaccines is the
risk of reversion to virulence and although they are currently
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FIGURE 1 | Brief overview of the anti-macrophage screen workflow.
Recombinant genomic libraries of the sequenced clinical isolate
B. pseudomallei K96243 were produced in E. coli (1), end-sequenced
and subsequently screened for cytotoxicity against murine
macrophages (2). Library clones shown to reduce macrophage viability
by 40% or more are classed as positive and the end sequences of
these positive clones are aligned onto the genome sequence (3). Each
anti-macrophage locus, or region of interest (ROI), is then described
as the minimum region of genetic overlap covered by two or more
positive clones (4).
the most effective vaccines studied in mice it is unlikely that
they would be used in humans (Sarkar-Tyson and Titball, 2010).
Less research has been focused on the development of subunit
vaccines (mainly as a putative antigen needs to first be iden-
tified) and those investigated are far less effective (Patel et al.,
2011). This screen represents a novel method that can be used
to directly identify potential recombinant subunit vaccines. The
design of the screen means that any active anti-macrophage
products identified are successfully expressed within recombinant
E. coli. Recombinant subunit vaccines are an attractive proposi-
tion as they eliminate the safety issues associated with subunit
purification from large cultures of the pathogen itself (Liljeqvist
and Stahl, 1999).
The original screen revealed over 100 anti-macrophage related
loci on both chromosomes 1 and 2 of B. pseudomallei strain
K96243. Several functional classes were repeatedly identified;
putative secondary metabolite synthesis gene clusters (NRPSs
and PKSs), signal response and regulation systems (methyl-
accepting chemotaxis proteins, two-component sensor systems,
AraC and LysR family regulators), phage-related elements, resis-
tance (drugs, metals, reactive oxygen species), adhesion and
biofilm formation. The largest number of coding sequences
(CDSs) detected however related to toxin/enzyme production
(hemolysins, proteases, phospholipases) or transport and secre-
tion (ABC transporters, autotransporters, efflux transporters,
and components of Type III and Type VI secretion systems).
Examples of putative vaccine candidates from different func-
tional classes discussed in the following text are summarized in
Table 1.
TRANSPORTERS AND SECRETION SYSTEMS
ABC transporter and autotransporter-related proteins are draw-
ing considerable interest as potential vaccine candidates given the
surface association of their component proteins which may be
exposed to the immune system upon B. pseudomallei infection
(Garmory and Titball, 2004; Lazar Adler et al., 2011). ABC trans-
porters have a known role in bacterial survival and pathogenicity,
22 of the 105 predicted K96243 ABC transporters were detected
by the screen (Harland et al., 2007b; Dowling et al., 2010). Of par-
ticular interest among the detected loci are the lipopolysaccharide
(LPS) biosynthesis operon and wzt ABC transporter (Table 1).
This particular finding suggests that an active LPS can be success-
fully constructed in a recombinant system. Given that LPS elicits
strong immune responses this could make it an attractive vaccine
candidate. Further, this screen detected 5 out of the 11 docu-
mented autotransporters in K96243 and interestingly detects both
BPSS0796 (BoaA) and BPSL1705 (BoaB), these trimeric auto-
transported adhesins are implicated in adhesion to epithelial cells
and are shown to have immunogenic properties (Tiyawisutsri
et al., 2007; Balder et al., 2010).
Recent advances have been made regarding Type VI secre-
tion machinery proteins; in particular the Hcp family, as sub-
unit vaccine candidates (Burtnick et al., 2011). Three of the
six documented hcp encoded proteins; Hcp5 (BPSS099), Hcp4
(BPSS0171), and Hcp6 (BPSL3015), were within ROI detected
by this screen. However, research so far demonstrates that puri-
fied Hcp2 gives the highest-level protection (80%) to BALB/c
mice inoculated with a lethal dose of B. pseudomallei. Burtnick
et al. demonstrated T6SS 1 as a major virulence determinant
for B. pseudomallei with deletion of hcp1 resulting in higher
LD50s and growth defects compared to wild-type B. pseudomallei.
Deletion of vgrG1 from this system also displayed the same results
demonstrating its importance in secretion of Hcp1 (Burtnick
et al., 2011). VgrG proteins play an important role in host cell
cytotoxicity as well as forming the secretion machinery itself and
are present on the surface of the pathogen, several VgrG CDSs
were identified by the screen (Pukatzki et al., 2009; Suarez et al.,
2010).
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Table 1 | Examples of putative vaccine candidates identified.
Functional class Example vaccine candidate CDS References
ABC transporter LPS biosynthesis operon plus wzt ABC transporter BPSL2672-
BPSL2688
Garmory and Titball, 2004; Harland et al., 2007b
Autotransporter BoaA
BoaB
BPSS0796
BPSL1705
Tiyawisutsri et al., 2007; Balder et al., 2010;
Lazar Adler et al., 2011
Type VI secretion Hcp proteins (inc. Hcp4, Hcp5, Hcp6) and VgrG
proteins
numerous Pukatzki et al., 2009; Suarez et al., 2010;
Burtnick et al., 2011
Toxin Burkholderia Lethal Factor 1 BPSL1549 Cruz-Migoni et al., 2011
Enzyme Phospholipase D BPSS1381 McKean et al., 2007; Driskell et al., 2009
Non-hemolytic phospholipase PLC-3 BPSS0067 Tuanyok et al., 2006
Adhesion Filamentous hemagglutinin-like BPSS1721-
BPSS1735
Sato et al., 1981; Kimura et al., 1990; Dowling
et al., 2010
Secondary metabolism SylA-like (BylA) BPSS1263-
BPSS1269
Groll et al., 2008; Dowling et al., 2010
Hypothetical protein Putative toxins BPSL0590
BPSL0591
Dowling et al., 2010
TOXINS, ENZYMES, AND HYPOTHETICAL PROTEINS
One of the anti-macrophage regions identified contains a puta-
tive Phospholipase D-like protein (BPSS1381) (Dowling et al.,
2010). Mutations of Phospholipase D proteins in the pathogens
Corynebacterium pseudotuberculosis and Rickettsia prowazekii, in
which the protein is a major virulence factor, have shown poten-
tial as live-attenuated vaccines (McKean et al., 2007; Driskell
et al., 2009). Further characterization is warranted to determine
if this phospholipase D-like protein may be of use as a poten-
tial vaccine candidate for B. pseudomallei. Another loci of interest
encodes the putative toxin PLC-3 (non-hemolytic phospholipase)
which has been shown to be strongly upregulated in a hamster
model of melioidosis and a mutant displays an LD50 significantly
higher than wild-type B. pseudomallei parent strain (Tuanyok
et al., 2006). These data highlight PLC-3 as a potential vaccine
candidate warranting further investigation.
Approximately 30% of B. pseudomallei genes encode hypothet-
ical proteins whose biological functions are yet to be established.
These hypothetical proteins are a potential source of novel vir-
ulence factors, and indeed potential vaccine candidates. The
anti-macrophage screen promotes the identification of hypo-
thetical proteins with anti-macrophage functions. One positive
region described by the screen contained two large adjacent
CDSs, BPSL0590 and BPSL0591, encoding hypothetical pro-
teins. The position-specific-iterative BLAST (psi-BLAST) algo-
rithm predicted homology within BPSL0590 and BPSL0591 to
known toxins from other pathogens. Both contain domains with
homology to the Toxin complexes (Tc’s) from Photorhabdus,
further the predicted N-terminal of BPSL0590 has homology
to the Salmonella enterica virulence associated protein or SpvB.
Macrophages treated with lysate from recombinant E. coli library
clones expressing BPSL0590 and BPSL0591 show altered actin
cytoskeletal morphology, multi-nucleation, and apoptosis illus-
trating that these may be novel toxins (Dowling et al., 2010).
Recently a novel toxin has been described in B. pseudomallei
K96243 with similarity to the potent CNF1 toxin from E. coli
and has been named “Burkholderia Lethal Factor 1” or BLF1
(BPSL1549) (Cruz-Migoni et al., 2011). BLF1 has the ability to
inhibit helicase activity and thus protein synthesis. BLF1 was pre-
viously described as a hypothetical protein given that similarity
to CNF1 is based on structural rather than sequence homology.
BLF1 mutants were attenuated in their ability to kill mice and
purified toxin was lethal upon injection indicating the important
nature of this toxin in B. pseudomallei virulence (Cruz-Migoni
et al., 2011). The BPSL1549 CDS that encodes BLF1 was iden-
tified within a positive locus pulled out by the anti-macrophage
screen. Of note, the toxin is flanked by two ABC transporter sys-
tems (BPSL1545-BPSL1546 and BPSL1548) also contained with
the anti-macrophage region of interest that may be involved in
secretion of BLF1. The utility of BLF1 as a toxoid vaccine has
yet to be explored. There are a further 28 anti-macrophage loci
out of the 113 described in the screen which contain at least one
hypothetical protein. These are yet to be investigated via detailed
protein and structural prediction algorithms to identify active
sites or homologies. However, as exemplified by BLF1, such hypo-
thetical proteins warrant further research as a source of potential,
currently hidden, virulence factors, and hopefully future vaccine
candidates.
ADHESINS
Adhesins make attractive vaccine candidates, as they are surface
expressed and likely therefore to be presented to the immune
system upon infection. Adhesins are often key virulence determi-
nants allowing the initial attachment of the invading pathogen
to host cells. The effectiveness of the Filamentous hemagglu-
tinin (FHA) of Bordetella pertussis as an antigen has long been
utilized in vaccines against Pertussis (Sato et al., 1981). The
region BPSS1721-BPSS1735 identified as an anti-macrophage
locus encodes proteins with predicted homology to B. pertus-
sis FHA. Macrophages treated with library clones expressing the
region showed dramatic actin alterations and apoptotic nuclei.
Of note, B. pertussis FHA is successful at preventing adherence
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of the pathogen to the respiratory epithelium when introduced
as a protective antigen via intranasal immunization (Kimura
et al., 1990). The role of this hemagglutinin-like protein in
B. pseudomallei infection has not so far been characterized.
Determination of whether this FHA homolog may prove useful
in protection against melioidosis, in particular disease contracted
via inhalation, could help in the formulation of a successful
vaccine.
SECONDARYMETABOLITES
Many of the anti-macrophage regions identified contained large
gene clusters associated with the non-ribosomal peptide syn-
thetase (NRPS) or polyketide synthase (PKS) systems used in the
production of peptides and small molecules. The role of such sec-
ondary metabolites in virulence is largely undescribed, however,
they may be used to promote intracellular survival or produc-
tion of toxic products and could provide part of the underlying
metabolism supporting latent disease. One such anti-macrophage
region described by the screen encodes an NRPS gene cluster
(BylA) with homology to the SylA (Syringolin A) producing genes
from Pseudomonas syringae (Dowling et al., 2010). SylA is a pro-
teasome inhibitor and potent cytotoxin (Groll et al., 2008). NRPS
and PKS gene clusters and their secondary metabolite products
are an unexplored class of vaccine candidates. Purified secondary
metabolites may be directly useful as antigens, and there is also the
potential for mutating NRPS/PKS gene for use as live-attenuated
vaccines.
PREVIOUSLY EVALUATED VACCINE CANDIDATES IDENTIFIED BY THE
SCREEN
The subunit vaccine candidate PotF and the asd (aspartate-β-
semialdehyde dehydrogenase) gene whose mutation has been
investigated for use as a live-attenuated vaccine were re-identified
(Harland et al., 2007a; Norris et al., 2011). Asd amino acid prod-
ucts have a role in cell wall biosynthesis and are likely to be
necessary for growth and replication (Norris et al., 2011). The
asd gene may have equipped recombinant library E. coli with
an increased growth ability enabling them to cause cytotoxicity
by overwhelming the macrophages. PotF is an ABC transporter-
associated protein involved in putrescine transport documented
as necessary for virulence in other bacterial pathogens, putatively
involved in host cell attachment and virulence as in a homologous
ABC transporter in the plant pathogen Agrobacterium tumefa-
ciens and for invasion and intracellular survival in Salmonella
enterica (Matthysse et al., 1996; Jelsbak et al., 2012). Outer mem-
brane protein A (OmpA) members Omp3 and Omp7 (Hara et al.,
2009) and also Omp85 (Su et al., 2010) have been researched
as subunit vaccine candidates, however, protection afforded was
no greater than with other strategies. Several Omps were iden-
tified by this screen, but not those so far tested as candidates.
Interestingly, the majority of previously studied vaccine candi-
dates were not re-identified. The main reason for this is that the
screen looks specifically for toxicity towardmacrophages. Existing
subunit candidates were selected for potential immunogenicity
and are not necessarily cytotoxic. Most of the genes selected
for mutation in the development of live-attenuated vaccines are
involved in biosynthetic processes and expression of these in
library strain E. coli may not result in production of cytotoxic
moieties or cytotoxicity as a result of enhanced bacterial growth
and overwhelming.
ADVANTAGES AND LIMITATIONS
There are several advantages of using gain of function screens
for discovering virulence factors and vaccine candidates. Firstly,
they overcome functional redundancy to unmask virulence fac-
tors which may be compensated in mutants. B. pseudomallei
has a large genome and the ability to survive in a wide range
of environmental niches. This suggests that functional redun-
dancy is likely among virulence factors with various genes or
genetic regions able to compensate mutation to produce success-
ful infection. Secondly, the screens cannot only be used to directly
isolate candidates, which may be useful in the development of
recombinant subunit vaccines, but also subunit vaccines, DNA
vaccines, and live-attenuated vaccines. The screen works by iden-
tifying factors that are effective against immune cells via successful
recombinant expression in E. coli. Production of vaccines via
recombinant expression is safer, and more efficient, than purify-
ing from the pathogen itself. Further, the technique narrows down
the minimum genetic area needed to produce a response. So far
purified proteins have had limited success as vaccines, mainly as
this approach requires actual identification of virulence factors or
antigenic determinants as candidates first. This problem is tackled
by the screening process, which is also able to identify hypo-
thetical proteins with a role in macrophage toxicity. Identifying
virulence factors and/or antigens has previously proved difficult
for intracellular bacteria (Titball, 2008; Patel et al., 2011). We are
currently developing a further novel genomic screen to look for
virulence factors involved in intracellular survival and persistence.
Thirdly, such screening is rapid and cost-effective, without need-
ing Class III safety facilities and trained staff. Such requirements
can restrict the progress of vaccine candidate identification and
testing.
One limitation of the screen is the size range of DNA fragments
cloned into the BAC and fosmid libraries used (10 kb and 40 kb
respectively) therefore any factors above this size will be missed
(for example complete type III secretion systems). For successful
screening high library quality, in particular good genomic cov-
erage, is necessary to allow repeated identification of cytotoxic
clones containing the same genetic region in order to generate
confidence in the ROIs identified. The E. coli used in screens to
date are not modified with for example, regulatory systems, func-
tional secretion systems, or promoters of secondary metabolite
production. Although this may limit what is detected, it is also
serves as an advantage, as any cytotoxic activity detected is simply
a result of successful production by the recombinant library E. coli
expressing a B. pseudomallei DNA fragment. This immediately
allows us to narrow down what can be produced in a recombinant
system and importantly identify the minimum genetic region
necessary to produce bioactivity in such a recombinant system, as
would be required for culture and production of a recombinant
subunit vaccine. Successful secretion/release from recombinant
E. coli and effector uptake by macrophages may also limit the fac-
tors detected. Some factors may achieve access to macrophages
as the cells take in solutes non-specifically from the extracellular
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media (inoculated with clone lysate preparation) via pinocyto-
sis/macropinocytosis. Further, some viable E. coli in the lysate
preparation appears necessary for toxicity in some cases.
PATHWAYS FOR FUTURE RESEARCH
The number of candidates identified by the gain of function
screen is large (>100). Combined approaches correlating datasets
obtained from techniques such as in vivo expression with this type
of recombinant screen will further narrow down key vaccine can-
didates for follow-up. Use of advanced cytotoxicity screens and
high-content phenotype screening will allow detailed functional
characterization of candidates. Further investigation of positive
regions identified will involve transposon mutagenesis to iden-
tify minimum region of activity/genes involved and sub-cloning
of these genes to confirm activity. Another useful next step would
be to measure the extent of the immune response of macrophages
challenged with the anti-macrophage factors identified from the
original screen by, for example, assaying nitric oxide production.
Screening for adherence and intracellular persistence will identify
factors involved in these aspects of B. pseudomallei infection. This
could prove valuable for development of live-attenuated vaccines
for which the issues of safety and potential latency of the mutant
B. pseudomallei bacteria are of major concern. Introducing addi-
tional mutations which will limit or prevent adherence to or
persistence within cells in the host could help to make this type of
vaccine more viable for use (Patel et al., 2011). These gain of func-
tion screens can be used to “mix andmatch” recombinant vaccine
candidates to investigate combinations for possible multivalent
subunit vaccines. A combination vaccine composed of polysac-
charide and protein presents the most promising formulation for
a melioidosis vaccine to date (Patel et al., 2011).
CONCLUDING REMARKS
By directly askingmacrophages which genomic regions ofB. pseu-
domallei express anti-macrophage gene products in a recombi-
nant library system we can begin to isolate virulence factors and
potential vaccine candidates. We can explore and characterize the
effects of single virulence factors provided that activity can be
reproduced in recombinant E. coli. This “gain of function” tech-
nique can be strengthened by combining with other methods, for
example, in vivo expression data, providing a powerful tool for
discovery, and prioritization of key vaccine candidates for future
research.
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